

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-4. (Canceled)

Claim 5. (Currently amended): A method according to claim 1 wherein the protein kinase C inhibitor is for the treatment of organ or tissue transplant rejection or for the prevention of graft-versus-host disease in a subject in need thereof, comprising administering to said subject an agent selected from the group consisting of 3-(1-methyl-1H-indol-3-yl)-4-[1-((1-pyridin-2-yl)methyl)-piperidin-4-yl]-1H-indol-3-yl]-pyrrole-2,5-dione, or 3-(1-methyl-1H-indol-3-yl)-4-[1-(piperidin-4-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, or and a pharmaceutically acceptable salt, hydrate or solvate thereof.

Claims 6-14. (Canceled)

Claim 15. (New): The method of claim 5, further comprising administering to said subject at least one additional agent selected from an immunosuppressant and an immunomodulatory drug.